Clinical trials: Liver Cell Carcinoma Non-resectable
Hepatocellular Carcinoma Non-resectable
Selective Internal Radiation Therapy and 188Re-SSS Lipiodol Treatment for Liver Cancer (Lip-Re2)
The goal of this monocentric interventional study is to evaluate the efficacy, in terms of objective response rate, of the 188Re-SSS lipiodol SIRT in patients with non-operable HCC.
- Trial name
- Lip-Re2 (NCT05797870)
- Testing
- Selective Internal Radiation Therapy with 188Re-SSS lipiodol
- Where
- France
- Volunteers
- 16 people
- Sponsor
- Center Eugene Marquis
Cadonilimab and Lenvatinib
Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma
This study is a single-arm, open-label, exploratory clinical trial designed to assess the effectiveness and safety of the combination therapy of Cadonilimab and Lenvatinib for conversion treatment in unresectable hepatocellular…
- Trial name
- NCT06215651
- Testing
- Cadonilimab lenvatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma
MRI With Gadoxetate Disodium in Measuring Tumors in Patients With Liver Cancer
This pilot clinical trial studies magnetic resonance imaging (MRI) with gadoxetate disodium in measuring tumors in patients with liver cancer.
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage 0 Adult Hepatocellular Carcinoma, BCLC Stage A Adult Hepatocellular Carcinoma
- Trial name
- NCT02578602
- Testing
- Gadoxetate Disodium, Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Southern California
Transarterial Chemoembolization, Systemic Therapy
Prospective Collection of Therapeutic Efficacy and Safety Data in Patients with Unresectable Hepatocellular Carcinoma
The malignant degree of middle and advanced liver cancer is very high, and the survival prognosis of patients is very poor. TACE is currently the standard treatment for unresectable liver cancer recommended by several…
- Conditions
- Transarterial Chemoembolization, Systemic Therapy, Unresectable Hepatocellular Carcinoma
- Trial name
- NCT06788353
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Sun Yat-sen University
Liver Cancer
Radiation Therapy in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. This may be an effective treatment for liver cancer. PURPOSE: This phase I/II trial is studying the side effects and best dose of external-beam radiation…
- Trial name
- NCT00777894
- Testing
- 3-dimensional conformal radiation therapy, intensity-modulated radiation therapy, stereotactic body radiation therapy
- Where
- 6 sites in Netherlands, Switzerland
- Volunteers
- 18 people
- Sponsor
- Swiss Cancer Institute
Hepatocellular Carcinoma Non-resectable
A Phase 2, Single Arm Study of Cabozantinib in Patients With Hepatocellular Carcinoma Who Have Received Prior Atezolizumab and Bevacizumab
Hepatocellular carcinoma (HCC) is the most common liver cancer and a leading cancer death worldwide. Currently, atezolizumab and bevacizumab combination is the standard of care for patients with advanced HCC.
- Trial name
- CPAB (NCT06535737)
- Testing
- Cabozantinib
- Volunteers
- 40 people
- Sponsor
- Chulalongkorn University
Liver Neoplasms, Carcinoma, Hepatocellular
A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) Participants
The purpose of this study is to describe the following safety and the efficacy of Lenvima for the first-line treatment indication of participants with uHHC in the post marketing setting: (1) Serious adverse events and serious…
- Trial name
- NCT05225207
- Testing
- Non-interventional
- Where
- 42 sites in South Korea
- Volunteers
- 658 people
- Sponsor
- Eisai Korea Inc.
Cancer
PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer
RATIONALE: PV701 may be able to kill tumor cells while leaving normal cells undamaged. PURPOSE: Phase I trial to study the effectiveness of PV701 in treating patients who have advanced or recurrent ovarian epithelial, fallopian…
- Trial name
- NCT00055705
- Testing
- PV701
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Unresectable Hepatocellular Carcinom
Conversion Therapy Using TACE/HAIC With Anti-Angiogenic and Immunotherapy for Initially Unresectable Hepatocellular Carcinoma Achieving Complete Response or Resectability, Followed by Surgery or Continued Systemic Treatment: A Prospective Cohort Study
This is a prospective cohort study designed to evaluate the effectiveness and safety of two post-conversion treatment strategies for patients with initially unresectable hepatocellular carcinoma (uHCC).
- Trial name
- THAI-CONVERT (NCT07206511)
- Volunteers
- 278 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma
Gemcitabine, Oxaliplatin in Combination With Bevacizumab in Patients With Hepatocellular Carcinoma
The purpose of this study is to test the safety of bevacizumab when given in combination with gemcitabine and oxaliplatin and to see what effects (good or bad) it has on patients with hepatocellular carcinoma.
- Trial name
- NCT00142467
- Testing
- Gemcitabine, Oxaliplatin, Bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Massachusetts General Hospital
Liver Cell Carcinoma Non-resectable
Observational Prospective Study on Chemoembolization With Doxorubicin for Unresectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the fifth most common type of cancer in men and the seventh in women and is the third most common cause of death from cancer worldwide.
- Trial name
- DEBDOX (NCT01891539)
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- International Group of Endovascular Oncology
Liver Cancer
Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00514228
- Testing
- sunitinib malate
- Where
- Switzerland
- Volunteers
- 45 people
- Sponsor
- Swiss Cancer Institute
Hepatocellular Carcinoma
Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma
To compare the clinical outcomes of Lenvatinib treatment alone or Lenvatinib + ADI-PEG20 combination treatment in advanced HCC patients with BCLC stage C.
- Trial name
- NCT06034977
- Testing
- ADI-PEG20
- Where
- Taiwan
- Volunteers
- 120 people
- Sponsor
- Chang Gung Memorial Hospital
Stage IV Melanoma, Advanced Lung Cancer
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
The purpose of this study is to refine and pilot test educational material developed to educate and support patients receiving immunotherapy for advanced cancer.
- Conditions
- Stage IV Melanoma, Advanced Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Non-Small Cell Lung Carcinoma
- Trial name
- UPLIFT (NCT04670445)
- Testing
- Educational Video and QPL List, Usual Care
- Where
- United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Hepatocellular Carcinoma Non-resectable
Adjuvant Stereotactic Body Radiation Therapy After Trans-arterial Chemoembolization in Hepatocellular Carcinoma
The study investigates the adjuvant SBRT following TACE in early and intermediate stages HCC not amenable for surgical resection.
- Trial name
- ASTrH (NCT04996914)
- Testing
- TACE, SBRT
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- RWTH Aachen University
Localized Non-Resectable Adult Hepatocellular Carcinoma
Stereotactic Body Radiotherapy for Unresectable Hepatocellular Carcinoma
1. Background 1.1. Hepatocellular carcinoma (HCC) HCC is the third most common cause of cancer death globally. It is also the second cause of cancer mortality in Korea, despite the incidence of HCC was fifth.
- Trial name
- SBRT for HCC (NCT01910909)
- Testing
- Stereotactic body radiotherapy
- Where
- South Korea
- Volunteers
- 56 people
- Sponsor
- Samsung Medical Center
Hepatocellular Carcinoma
Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC
Hepatocellular carcinoma (HCC) is a common disease with high mortality. More than 80% patients receive a diagnosis when their tumors are too advanced for curative approaches and have a dismal prognosis.
- Trial name
- NCT04011033
- Testing
- iNKT cells, Human recombinated Interleukin-2, TAE/TACE
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing YouAn Hospital
Hepatocellular Carcinoma (HCC)
Dapagliflozin Add-on in Unresectable HCC With Metabolic Syndrome
The goal of this interventional study (clinical trial) is to evaluate the efficacy and safety of adding dapagliflozin to first-line standard therapy in patients with unresectable hepatocellular carcinoma (HCC) and comorbid…
- Trial name
- NCT07729592
- Testing
- Dapagliflozin, Donafenib, Tislelizumab
- Volunteers
- 44 people
- Sponsor
- Sun Yat-sen University
Colorectal Cancer, Islet Cell Tumor
Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
- Conditions
- Colorectal Cancer, Islet Cell Tumor, Liver Cancer, Metastatic Cancer
- Trial name
- NCT00019786
- Testing
- isolated perfusion, melphalan, conventional surgery
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatocellular Carcinoma
OREIOS International Study
Considering the treatment landscape with its dynamic algorithms and new approaches of sequencing, it is important to identify patient management patterns and survival outcomes arising from the current standard of care.
- Trial name
- OREIOS (NCT05239507)
- Where
- 21 sites in Brazil, Egypt and 9 more
- Volunteers
- 1,127 people
- Sponsor
- AstraZeneca